A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Trial Details

NCT ID
NCT03592472
Phase
PHASE3
Sponsor
Xynomic Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Pazopanib
  • Abexinostat
  • Placebo
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Sacramento, California, United States|38.58157,-121.4944
  • San Francisco, California, United States|37.77493,-122.41942
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • New Orleans, Louisiana, United States|29.95465,-90.07507

Key Eligibility Criteria

  • To be enrolled in the study, patients will be required to meet all of the following criteria:
  • Patients aged ≥ 18 years at time of study entry.
  • Patients have histologically confirmed RCC with clear cell component.
  • Patients have locally advanced and unresectable or metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →